US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

60.92

-0.4491-0.73%

Volume:1K

Turnover:90.87K

Market Cap:269.24M

PE:19.93

High:61.34

Open:61.15

Low:60.82

Close:61.36

52wk High:64.10

52wk Low:39.36

Shares:4.42M

Float Shares:4.42M

Volume Ratio:0.12

T/O Rate:0.03%

Dividend:1.53

Dividend Rate:2.51%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Priovant Therapeutics - Lisraya NOW Available in the U.S.

THOMSON REUTERS

Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.

THOMSON REUTERS

US FDA Approves Roivant-Priovant's Skin Disease Drug

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis

THOMSON REUTERS

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS

Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/PTH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":60.915,"timestamp":1788533062100,"preClose":61.3641,"halted":0,"volume":1490,"delay":0,"changeRate":-0.00731861137049189,"floatShares":4420000,"shares":4420000,"eps":3.057033,"marketStatus":"Trading","change":-0.4491,"latestTime":"09-04 10:44:59 EDT","open":61.15,"high":61.34,"low":60.82,"amount":90870.68662,"amplitude":0.008474,"askPrice":60.9,"askSize":700,"bidPrice":60.77,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788552000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":61.3641,"sharesOutstanding":2480000,"nav":61.35956,"aum":274890828.8,"dividendRate":0.025063,"bidAskSpread":0.001745,"postHourTrading":{"tag":"盘后","latestPrice":61.35,"preClose":61.3641,"latestTime":"19:30 EDT","volume":11,"amount":675.5846,"timestamp":1788478205997,"change":-0.0141,"changeRate":-0.00023,"amplitude":0},"volumeRatio":0.118366,"impliedVol":0.1181,"impliedVolPercentile":0.4683},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4420000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.118366,"shares":4420000,"dividePrice":1.5267,"high":61.34,"amplitude":0.008474,"preClose":61.3641,"low":60.82,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":60.915,"committee":-0.75,"eps":3.057033,"divideRate":0.025063,"volume":1490,"delay":0,"ttmEps":3.057033,"open":61.15,"prevYearClose":49.701,"prevWeekClose":61.0661,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":61.0661,"twentyDayClose":60.3556,"sixtyDayClose":48.9337},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662080615","title":"Priovant Therapeutics - Lisraya NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080615?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858916,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA83F05F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080613","title":"Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080613?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858916,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA83F05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662806990","title":"US FDA Approves Roivant-Priovant's Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662806990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662806990?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:26","pubTimestamp":1787858771,"startTime":"0","endTime":"0","summary":"US FDA approves Roivant-Priovant's skin disease drugAug 27 (Reuters)-The U.S. Food and Drug Administration said on Thursday it approved a treatment from RoivantROIV.Oand partner Priovant Therapeutics for dermatomyositis, making it the first oral drug for the skin disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O1TO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080316","title":"FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080316","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080316?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:18","pubTimestamp":1787858285,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Approves First Oral Drug Indicated To Treat Dermatomyositis In AdultsAug 28 (Reuters)-FDA:FDA: FDA APPROVES FIRST ORAL DRUG INDICATED TO TREAT DERMATOMYOSITIS IN ADULTSFDA: LISRAYA IS THE FIRST FDA-APPROVED ORAL TREATMENT OPTION FOR PATIENTS WITH DERMATOMYOSITIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662803550","title":"FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662803550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662803550?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:14","pubTimestamp":1787858053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008458","title":"Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008458","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662008458?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:21","pubTimestamp":1787847665,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","LU0109394709.USD","IE0009355771.USD","RVMD","BBH","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE0009354923.USD","IDNA","PTH","IE00B4R5TH58.HKD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704855","title":"Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704855","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662704855?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:35","pubTimestamp":1787830554,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era** Revolution Medicines'RVMD.Ogroundbreakingpancreatic cancer drug, Rasonque, received the U.S. FDA approval on W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0320765992.SGD","CANC","IDNA","PTH","IE00BJT1NW94.SGD","LU0889565916.HKD","RVMD","IE00BFTCPJ56.SGD","BBH","IE0009355771.USD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","IE00B2B36J28.USD","BK4585","IE0009355771.USD","XBI","BK4539","IE00BJJMRZ35.SGD","PTH","BK4588","LU0128526141.USD","BK4581","RVMD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0029874061.USD","IE00BFTCPJ56.SGD","BK4139","IMRX","IE00BJT1NW94.SGD","LABU","LU0889565916.HKD","IE0002141913.USD","IE0009354923.USD","BK4137","CANC","LU0320765992.SGD","BK4563","IDNA","HCSG","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192894793","title":"Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1192894793","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192894793?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:42","pubTimestamp":1787820126,"startTime":"0","endTime":"0","summary":"Jinbo Bio, a leading player in the recombinant collagen sector, recently published its interim report for the first half of 2026, revealing a notable setback in its growth trajectory. The financial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HART","MEDX","BK1100","IEIH","LNGR","PTH","BK1574","AGNG","MDEV","09996","LGHT","RSPH","GDOC","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662988724","title":"Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230","url":"https://stock-news.laohu8.com/highlight/detail?id=2662988724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662988724?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:38","pubTimestamp":1787798329,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44N0VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE0009354923.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IDNA","BBH","LU0109394709.USD","LU0889565916.HKD","RVMD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","PTH","IE0002141913.USD","CANC","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662574411","title":"Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2662574411","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662574411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:15","pubTimestamp":1787775315,"startTime":"0","endTime":"0","summary":"• BrightSpring reported strong second-quarter revenue and raised its full-year guidance.\n• Wall Street analysts maintained buy ratings with an average price target of $78.97.\n• Annual revenue reached $12.91 billion with a net profit of $190.67 million.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262133901-market-movers-btsg-20260826","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","PSCH","LU2324357040.USD","LU2468319806.SGD","PTH","LU2089984988.USD","BTSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749358","title":"Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749358","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662749358?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:20","pubTimestamp":1787768430,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  once-daily oral Rasonque tablets for the treatment of metastatic pancreatic cancer are available in the US at a price of $39,800 for a 30-day supply, the company said Wednesday in a regulatory filing.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.Price: 215.95, Change: +4.57, Percent Change: +2.16","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE00BJT1NW94.SGD","IE0009354923.USD","IE00BFTCPJ56.SGD","BBH","IE0002141913.USD","BK4139","LU0109394709.USD","IE00B4R5TH58.HKD","PTH","CANC","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","RVMD","IE00B2B36J28.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746776","title":"Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746776","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746776?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:02","pubTimestamp":1787767375,"startTime":"0","endTime":"0","summary":"Price: 215.72, Change: +4.34, Percent Change: +2.05","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD","RVMD","IDNA","BK4139","IE0009354923.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BBH","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","CANC","PTH","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662462057","title":"Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662462057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662462057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:56","pubTimestamp":1787766961,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","IDNA","BBH","IE00BFTCPJ56.SGD","LU0889565916.HKD","RVMD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0009354923.USD","CANC","IE00BJT1NW94.SGD","PTH","BK4139","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746411","title":"Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746411","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766356,"startTime":"0","endTime":"0","summary":"Revolution Medicines posts investor presentation on RASONQUE FDA approvalRevolution Medicines released an investor presentation covering U.S. FDA approval of RASONQUE (daraxonrasib) for metastatic pan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4qMXCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","PTH","IE00BJJMRZ35.SGD","RVMD","IE00BJT1NW94.SGD","CANC","IDNA","BBH","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU0889565916.HKD","IE0009354923.USD","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","TECB","BMED","IE0009354923.USD","FRTY","GNMX","IEIH","IE00BJT1NW94.SGD","BK4139","CANC","PSCH","XLVX","LU0320765992.SGD","IE00BFTCPJ56.SGD","MEDI","IBB","IE00B2B36J28.USD","RSPH","BBP","LFSC","BK4585","MRNX","BBH","NVIB","BK4588","LU0889565916.HKD","PINK","IE0009355771.USD","IE00BJJMRZ35.SGD","PTH","TBXU","LU0109394709.USD","IE0002141913.USD","GDOC","RVMD","IDNA","SYNB","LABU","IYH","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","BMED","SYNB","IE0009354923.USD","GDOC","FRTY","CANC","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BBP","PINK","RSPH","RVMD","TBXU","XLVX","NVIB","IE00B2B36J28.USD","GNMX","PSCH","TECB","IBB","IE0009355771.USD","LFSC","MRNX","LABU","IDNA","IE00B4R5TH58.HKD","PTH","BK4588","LU0109394709.USD","LU0889565916.HKD","IYH","LU0320765992.SGD","BBH","BK4139","IEIH","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745207","title":"Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745207?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763576,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA6XRCYX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0889565916.HKD","BBH","IE0009355771.USD","IDNA","IE00B2B36J28.USD","IE0009354923.USD","IE00BJJMRZ35.SGD","CANC","LU0109394709.USD","PTH","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662452007","title":"U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662452007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662452007?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA6XRCYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","IE0009354923.USD","CANC","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","RVMD","BK4139","IDNA","IE0002141913.USD","IE00BFTCPJ56.SGD","PTH","IE0009355771.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759746","title":"U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759746","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763540,"startTime":"0","endTime":"0","summary":"RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent syste","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTDU","LU1720051108.HKD","IE0002141913.USD","LU0124384867.USD","BK4588","CANC","LU1720051017.SGD","BK4023","TTD","BK4605","BK4009","LU0724618433.USD","IDNA","LABU","LU2487616109.SGD","SRET","BK4141","ON","BBH","BK4512","BK4139","LU0109394709.USD","IE00B4R5TH58.HKD","LU2360107325.USD","ONG","LU1861220033.SGD","LU1978683503.SGD","BK4585","ITT","IE00BZ199S13.USD","IE0009355771.USD","LU1854103824.USD","IE00B2B36J28.USD","IE00BD6J9T35.USD","IE0009354923.USD","PFS","PTH","BK4225","LU0320765992.SGD","ONX","LU0053671581.USD","LU0889565916.HKD","LU1861219969.SGD","LU0210528500.USD","L","IE00BJJMRZ35.SGD","RVMD","HR","EMA","BK4613"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}